Investors & Media

What’s new.

Press releases

Press releases.

November 14th 2024

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

November 14th 2024

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

October 29th 2024

Immutep Quarterly Activities Report Q1 FY25

more

Investor updates

Investor updates.

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

more

Analyst reports

Analyst reports.

November 14th 2024

Baird - INSIGHT-003 Data Adds Support for Efti in NSCLC Ahead of Phase 3; Rated OP, US$7 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

November 14th 2024

Maxim - Positive Survival Data for Efti Triple Combo in 1L NSCLC; Bodes Well for Upcoming P3 Pivotal TACTI-004 Study in Same Setting - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

November 14th 2024

CLSA - Checking-off key points; Positive survival data in triple combo incrementally derisk TACTI-004; Maintain Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

more